NCT04892017: A Phase 1/2 Study of DCC-3116 in Patients With RAS/MAPK Pathway Mutant Solid Tumors |
|
|
| Recruiting | 1/2 | 173 | US | DCC-3116, Trametinib, Binimetinib, Sotorasib | Deciphera Pharmaceuticals LLC | Non-Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Solid Tumor | 08/27 | 08/28 | | |
NCT05957367: A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies |
|
|
| Recruiting | 1/2 | 94 | US | DCC-3116, Ripretinib, QINLOCK, DCC-2618 | Deciphera Pharmaceuticals LLC, Pfizer | GIST | 03/27 | 06/27 | | |
